




Only 23% of submitted analyses in pharma companies' AMNOG dossiers are considered in benefit assessment



-  **77%**
of analyses are not considered by IQWiG and/or G-BA
-  **7%**
of analyses are excluded with justification by IQWiG and/or G-BA
-  **16%**
of analyses are included by IQWiG and/or G-BA